Challenges to develop novel anti-inflammatory and analgesic drugs.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

• Publication date

  2017-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/wnan.1427PMID 27576790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurotrophic factors and their inhibitors in chronic pain treatment.

  2017cited by this paper
• Apremilast: A Review in Psoriasis and Psoriatic Arthritis

  2017cited by this paper
• The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis

  2016cited by this paper
• P2X ion channel receptors and inflammation

  2016cited by this paper
• A novel 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanal oxime compound is a potent Transient Receptor Potential Ankyrin 1 and Vanilloid 1 (TRPA1 and V1) receptor antagonist.

  2016cited by this paper
• Successes and failures of chemokine-pathway targeting in rheumatoid arthritis

  2016cited by this paper
• Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief

  2016cited by this paper
• HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis

  2016cited by this paper
• Transient receptor potential ankyrin 1 (TRPA1) receptor is involved in chronic arthritis: in vivo study using TRPA1-deficient mice

  2016cited by this paper
• Baricitinib in Patients with Refractory Rheumatoid Arthritis.

  2016cited by this paper
• Purinergic Mechanisms and Pain.

  2016cited by this paper
• Central N/OFQ-NOP Receptor System in Pain Modulation.

  2016cited by this paper
• The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats

  2016cited by this paper
• Expression of the semicarbazide-sensitive amine oxidase in articular cartilage: its role in terminal differentiation of chondrocytes in rat and human.

  2016cited by this paper
• Pharmacology and structure of P2Y receptors.

  2016cited by this paper
• Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation.

  2016cited by this paper
• Potassium channels in neuropathic pain: advances, challenges, and emerging ideas

  2016cited by this paper
• (420) NEO6860, a novel modality selective TRPV1 antagonist: results from a phase I, double-blind, placebo-controlled study in healthy subjects.

  2016cited by this paper
• A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile

  2016cited by this paper
• Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.

  2016cited by this paper
• Adenosine receptor targets for pain.

  2016cited by this paper
• The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis

  2016cited by this paper
• Identification of A3 adenosine receptor agonists as novel non‐narcotic analgesics

  2016cited by this paper
• Fatty acids, endocannabinoids and inflammation.

  2016cited by this paper
• A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase

  2016cited by this paper
• The role of TRPA1 in muscle pain and mechanical hypersensitivity under inflammatory conditions in rats.

  2015cited by this paper
• Physiology, Signaling, and Pharmacology of Galanin Peptides and Receptors: Three Decades of Emerging Diversity

  2015cited by this paper
• P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

  2015cited by this paper
• Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential.

  2015cited by this paper
• Apremilast: A Review in Psoriasis and Psoriatic Arthritis

  2015cited by this paper
• Discovery of a 1-isopropyltetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain.

  2015cited by this paper
• Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.

  2015cited by this paper
• Migraine and neuropeptides.

  2015cited by this paper
• Discovery of an 8-methoxytetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain without CYP inhibition liability.

  2015cited by this paper
• The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review.

  2015cited by this paper
• Drug developers reboot anti-NGF pain programmes

  2015cited by this paper
• Clinical and Preclinical Experience with TRPV1 Antagonists as Potential Analgesic Agents

  2015cited by this paper
• A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.

  2015cited by this paper
• Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study

  2015cited by this paper
• Delta opioid agonists: a concise update on potential therapeutic applications

  2015cited by this paper
• Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine.

  2015cited by this paper
• TRPA1 as a drug target—promise and challenges

  2015cited by this paper
• Antinociceptive effects of FTY720 during trauma-induced neuropathic pain are mediated by spinal S1P receptors

  2015cited by this paper
• Analgesic effect of a broad-spectrum dihydropyridine inhibitor of voltage-gated calcium channels

  2015cited by this paper
• Liver transplant associated with paracetamol overdose: results from the seven-country SALT study.

  2015cited by this paper
• Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations

  2015influential reference
• Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist.

  2015cited by this paper
• Targeting voltage-gated calcium channels in neurological and psychiatric diseases

  2015cited by this paper
• Two heterozygous Cav3.2 channel mutations in a pediatric chronic pain patient: recording condition-dependent biophysical effects

  2015cited by this paper
• Monosodium iodoacetate-induced inflammation and joint pain are reduced in TRPA1 deficient mice--potential role of TRPA1 in osteoarthritis.

  2015cited by this paper
• Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies

  2015cited by this paper
• Gaseous mediator-based anti-inflammatory drugs.

  2015cited by this paper
• The somatostatin receptor 4 agonist J-2156 reduces mechanosensitivity of peripheral nerve afferents and spinal neurons in an inflammatory pain model.

  2015cited by this paper
• A Phase 2 Study in Women with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) of the Novel P2X3 Antagonist AF-219

  2015cited by this paper
• Sigma-1 receptors and animal studies centered on pain and analgesia

  2015cited by this paper
• Transient receptor potential ankyrin 1 (TRPA1) antagonists.

  2015cited by this paper
• Involvement of the endocannabinoid system in osteoarthritis pain

  2014cited by this paper
• Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

  2014cited by this paper
• Calcitonin gene-related peptide: physiology and pathophysiology.

  2014cited by this paper
• Global Nav1.7 Knockout Mice Recapitulate the Phenotype of Human Congenital Indifference to Pain

  2014cited by this paper
• Mitogen-activated protein kinase phosphatase 1 as an inflammatory factor and drug target.

  2014cited by this paper
• Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.

  2014cited by this paper
• Two faces of inflammation: an immunopharmacological view.

  2014cited by this paper
• Purinergic receptor P2X₇: a novel target for anti-inflammatory therapy.

  2014cited by this paper
• Recent progress in sodium channel modulators for pain.

  2014cited by this paper
• N-type voltage-dependent Ca2+ channel in non-excitable microglial cells in mice is involved in the pathophysiology of neuropathic pain.

  2014cited by this paper
• Neuronal CC chemokines: the distinct roles of CCL21 and CCL2 in neuropathic pain

  2014cited by this paper
• Osteoarthritis pain: nociceptive or neuropathic?

  2014cited by this paper
• Protein kinase C and its inhibitors in the regulation of inflammation: inducible nitric oxide synthase as an example.

  2014cited by this paper
• Anti-allodynic effect of 2-(aminomethyl)adamantane-1-carboxylic acid in a rat model of neuropathic pain: a mechanism dependent on CaV2.2 channel inhibition.

  2014cited by this paper
• Cebranopadol: A Novel Potent Analgesic Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist

  2014cited by this paper
• Capsaicin and sensory neurones: a historical perspective.

  2014cited by this paper
• Therapeutic targeting of the Jak/STAT pathway.

  2014cited by this paper
• 1,4-Dihydropyridine derivatives with T-type calcium channel blocking activity attenuate inflammatory and neuropathic pain

  2014cited by this paper
• Transient receptor potential (TRP) channels: a clinical perspective

  2014cited by this paper
• Is there new hope for therapeutic matrix metalloproteinase inhibition?

  2014cited by this paper
• Tropomyosin receptor kinase inhibitors: a patent update 2009 – 2013

  2014cited by this paper
• Targeting Nerve Growth Factor (NGF) for Pain Management: What Does the Future Hold for NGF Antagonists?

  2014cited by this paper
• CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?

  2014cited by this paper
• Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions

  2014influential reference
• Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases.

  2014cited by this paper
• Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.

  2014cited by this paper
• Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1)

  2014cited by this paper
• CHAPTER 9:TRPV1 Antagonism: From Research to Clinic

  2014cited by this paper
• Transient Receptor Potential Channels as Drug Targets: From the Science of Basic Research to the Art of Medicine

  2014cited by this paper
• EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.

  2014cited by this paper
• Monoclonal Antibodies for Migraine: Preventing Calcitonin Gene-Related Peptide Activity

  2014cited by this paper
• Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis.

  2014influential reference
• TRPA1: A gatekeeper for inflammation.

  2013cited by this paper
• Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis

  2013cited by this paper
• Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.

  2013cited by this paper
• Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase‐1

  2013cited by this paper
• A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia

  2013cited by this paper
• Importance of glial activation in neuropathic pain.

  2013cited by this paper
• Metalloproteinases and their natural inhibitors in inflammation and immunity

  2013cited by this paper
• p38 MAPK Signaling in Pemphigus: Implications for Skin Autoimmunity

  2013cited by this paper
• Phosphodiesterase 4-targeted treatments for autoimmune diseases

  2013cited by this paper
• Ziconotide: a clinical update and pharmacologic review

  2013cited by this paper
• Genomic responses in mouse models poorly mimic human inflammatory diseases

  2013cited by this paper
• The role of endocannabinoids in pain modulation

  2013influential reference

• In silico insights into (±)-zanthonitidumine B: anti-Inflammatory potency and enantiomeric selectivity through molecular docking, DFT, and MEP studies

  2026cites this paper
• Anti-inflammatory activity of Silver Nanoparticles (AgNPs): An Updated Systematic review from in vivo, and in vitro studies.

  2026cites this paper
• Low-Grade Inflammation: Pathophysiological Mechanisms and Drug Targets in Irritable Bowel Syndrome with Diarrhea

  2026cites this paper
• Exploring the Pain-Relieving Potential: Unveiling Antinociceptive Properties in Animal Venoms and Toxins.

  2026cites this paper
• The Multifaceted Role of Cofilin in Inflammation and Pain Signaling

  2026cites this paper
• Novel Anti-Inflammatory Peptides from Co-Fermented Cottonseed Meal: Discovery via an Integrated In Silico and In Vitro Approach

  2026cites this paper
• Oxazepine-antipyrine hybrids: The inevitable robust anti-inflammatory agents - Synthesis, spectral characterization, in-silico and in-vitro corroboration

  2026cites this paper
• Targeting Genome Stability to Mitigate Human Aging and Disease.

  2025cites this paper
• Novel approaches for drug development against chronic primary pain: A systematic review.

  2025cites this paper
• MPN-12-NH2 shows potent antinociception effects by targeting opioid, cannabinoid, and neuropeptide FF receptors.

  2025cites this paper
• Distribution, Phytochemistry and Pharmacological Properties of the Genus Hugonia

  2025cites this paper
• Molecularly Engineered Controlled Release Systems for Local Anesthetics in Precise Pain Management

  2025cites this paper
• Immunomodulatory Effects of LSI312A on Dendritic Cells: A Novel Approach to Modulating Inflammatory Pathways

  2025cites this paper
• Pharmacological Perspective on the Neurobiology of PI3K-Akt-mTOR Signalling in Opioid Dependence.

  2025cites this paper
• Rapamycin ameliorates inflammatory pain via recovery of autophagy flux mediated by mammalian target of rapamycin (mTOR) signaling pathway in the rat spinal cord

  2025cites this paper
• Pathophysiology‐Directed Engineering of a Combination Nanoanalgesic for Neuropathic Pain

  2024cites this paper
• Spiro-fused indoline-quinazoline hybrids as smart bombs against TNF-α-mediated inflammation.

  2024cites this paper
• Preclinical evidence of the anti‐inflammatory effect and toxicological safety of aryl‐cyclohexanone in vivo

  2024cites this paper
• Role of SIRT5 in the analgesic effectiveness of moxibustion at ST36 in mice with inflammatory pain

  2023cites this paper
• The heptapeptide somatostatin analogue TT-232 exerts analgesic and anti-inflammatory actions via SST4 receptor activation: in silico, in vitro and in vivo evidence in mice.

  2023cites this paper
• Oxy210, a Semi-Synthetic Oxysterol, Exerts Anti-Inflammatory Effects in Macrophages via Inhibition of Toll-like Receptor (TLR) 4 and TLR2 Signaling and Modulation of Macrophage Polarization

  2022cites this paper
• Development of nanostructured lipid carriers loaded caffeic acid topical cream for prevention of inflammation in Wistar rat model

  2022cites this paper
• Human Somatostatin SST4 Receptor Transgenic Mice: Construction and Brain Expression Pattern Characterization

  2021cites this paper
• Analgesia, anesthesia, and euthanasia of aquatic animals

  2021cites this paper
• Hemokinin-1 as a Mediator of Arthritis-Related Pain via Direct Activation of Primary Sensory Neurons

  2021cites this paper
• Rosanortriterpenes A–B, Two Promising Agents from Rosa laevigata var. leiocapus, Alleviate Inflammatory Responses and Liver Fibrosis in In Vitro Cell Models

  2020cites this paper
• Peripheral nitric oxide signaling directly blocks inflammatory pain.

  2020cites this paper
• One‐pot three‐component azide‐alkyne cycloaddition: Synthesis of new pyrazole, 1,2, 3‐triazole , and oxadiazole tethered and their anti‐inflammatory , quantitative structure‐activity relationship, and docking studies

  2020cites this paper
• Characterization of Neurons Expressing the Novel Analgesic Drug Target Somatostatin Receptor 4 in Mouse and Human Brains

  2020cites this paper
• A novel view of the problem of Osteoarthritis in experimental rat model

  2020cites this paper
• Antinociceptive Effects of Lipid Raft Disruptors, a Novel Carboxamido-Steroid and Methyl β-Cyclodextrin, in Mice by Inhibiting Transient Receptor Potential Vanilloid 1 and Ankyrin 1 Channel Activation

  2020cites this paper
• Cannflavins - From plant to patient: A scoping review.

  2020cites this paper
• Expression and Activity of TRPA1 and TRPV1 in the Intervertebral Disc: Association with Inflammation and Matrix Remodeling

  2019cites this paper
• New pre-clinical evidence of anti-inflammatory effect and safety of a substituted fluorophenyl imidazole.

  2019cites this paper
• Cardiovascular Complications of Chronic Opium Consumption: A Narrative Review Article

  2019cites this paper
• Novel Drug-Like Somatostatin Receptor 4 Agonists are Potential Analgesics for Neuropathic Pain

  2019cites this paper
• Mechanisms of Botulinum Toxin Type A Action on Pain

  2019cites this paper
• Exploratory and locomotor activity, learning and memory functions in somatostatin receptor subtype 4 gene-deficient mice in relation to aging and sex

  2019cites this paper
• Analgesic effects of the novel semicarbazide‐sensitive amine oxidase inhibitor SZV 1287 in mouse pain models with neuropathic mechanisms: Involvement of transient receptor potential vanilloid 1 and ankyrin 1 receptors

  2018cites this paper
• Animal Venom Derived Toxins are NovelAnalgesics for Treatment of Arthritis

  2018cites this paper
• Antiepileptic drugs as analgesics/adjuvants in inflammatory pain: current preclinical evidence☆

  2018cites this paper
• The roles of special proresolving mediators in pain relief

  2018cites this paper
• Resolvin D2 Relieving Radicular Pain is Associated with Regulation of Inflammatory Mediators, Akt/GSK-3β Signal Pathway and GPR18

  2018cites this paper
• Design, Synthesis, and Biological Evaluation of Some New Benzostyrene Incorporated Phenyl Styryl Ketone Derivatives as COX-2 Inhibitors with Anti-Inflammatory Activity

  2017cites this paper
• Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm

  2017cites this paper
• Design, Synthesis and Anti-inflammatory Activity of Derivatives 10-R-3-Aryl-6,7-dihydro-2H-[1,2,4] triazino[2,3-c]quinazolin-2-ones of Spiro-fused Cyclic Frameworks.

  2017cites this paper